Inactivation of FTO in leukemia induced sensitivity of resistance cells to tyrosine kinase inhibitor [32], indicating that the FTO-m6A axis may serve as novel potential therapeutic target in human cancers [33]. This evidence concerns the gene FTO and cancer.